Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Idorn

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Therapeutic Advances in Endocrinology and Metabolism|July 25, 2022
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practiceBernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Kidney International|October 19, 2025
Response to the letter to the editor entitled "Semaglutide and kidney function: direct kidney protection or an artifact?"Vlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 25, 2010
Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolismMads Hornum, Peter Clausen, Thomas Idorn, et al.
Kidney International|January 2, 2014
The authors replyThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Kidney International|January 18, 2013
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal diseaseThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 1, 2013
Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal diseaseThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2014
Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patientsMorten B Jørgensen, Thomas Idorn, Filip K Knop, et al.
Biomedicines|September 28, 2023
Obesity-Related Kidney Disease: Current Understanding and Future PerspectivesFrederik F Kreiner, Philip Andreas Schytz, Hiddo J L Heerspink, et al.
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
The Journal of Clinical Endocrinology and Metabolism|April 10, 2014
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal diseaseThomas Idorn, Filip K Knop, Morten B Jørgensen, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Therapeutic Advances in Endocrinology and Metabolism|July 25, 2022
The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practiceBernt Johan von Scholten, Frederik Flindt Kreiner, Søren Rasmussen, et al.
Kidney International|October 19, 2025
Response to the letter to the editor entitled "Semaglutide and kidney function: direct kidney protection or an artifact?"Vlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 25, 2010
Kidney transplantation improves arterial function measured by pulse wave analysis and endothelium-independent dilatation in uraemic patients despite deterioration of glucose metabolismMads Hornum, Peter Clausen, Thomas Idorn, et al.
Kidney International|January 2, 2014
The authors replyThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Kidney International|January 18, 2013
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal diseaseThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 1, 2013
Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal diseaseThomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 17, 2014
Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patientsMorten B Jørgensen, Thomas Idorn, Filip K Knop, et al.
Biomedicines|September 28, 2023
Obesity-Related Kidney Disease: Current Understanding and Future PerspectivesFrederik F Kreiner, Philip Andreas Schytz, Hiddo J L Heerspink, et al.
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
The Journal of Clinical Endocrinology and Metabolism|April 10, 2014
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal diseaseThomas Idorn, Filip K Knop, Morten B Jørgensen, et al.
Pageof 4